RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingBusiness Wire • 04/16/24
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026Business Wire • 04/15/24
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024Business Wire • 04/05/24
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerBusiness Wire • 12/21/23
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingBusiness Wire • 12/19/23
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy PlatformBusiness Wire • 12/13/23
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.Business Wire • 11/16/23
RenovoRx Reports Third Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 11/14/23
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023Business Wire • 10/02/23
RenovoRx Reports Second Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 08/17/23
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) PlatformBusiness Wire • 07/20/23
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic CancerBusiness Wire • 06/29/23
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical TrialBusiness Wire • 06/01/23
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal CancerBusiness Wire • 05/25/23